Between GOOG, AMZN, and FB, computers know me better than my friends. Who would you like to buy a birthday gift for you? The computer or your friend? Best of both: I'd like the computer to make the decision, but make it look like my friend was the thoughtful one.
I know this is an investment board, but I suspect that those who in invest in FB are hoping that there isn't a backlash on this movement towards a new machine age.
Next thing you know, someone in gov't is going to work with FB to create the right mood before an election. Will it get your attention then?
No, I think they are awaiting therapy development news and most importantly, some positive comments from the FDA. The CEO shouldn't spend his time trying to prop up the price. If he did, that might seem like desperation and shorts would just sell more.
Selling their shares? I have no idea of what you are asking.
Share price is dropping because the trend is down and no one who wants to be long is willing to buy until there is a reversal in price. As long as there isn't any news to bring in buyers, the slide continues.
that made this sort of announcement regarding patented markers of prostate cancel would gain at least $50 million of market cap. For ROSG, 20 cent gain is about $2 million.
Unfortunately, the trend has been down for so long that any bump is seen as an opportunity to sell and reduce losses. It happens every time there is "positive news." Until they announce a license with actual dollar terms, I see no reason for a change in this pattern. I've been wrong before; I hope I'm wrong again.
This is from today's PR regarding indicators of prostate cancer. It is the first time I've head this from Mr. Berlin and perhaps he's finally seeing the need to begin to pay for R & D with money generated from sources other than secondaries.
I signed up years ago and tried to use it to communicate with business associates. Mixed results; haven't used it since.
If you're looking to add a biotech test company to your portfolio, NSPH is the better choice. ROSG is projected to do $1 million in sales next year and NSPH is projected to do 35 times as much. However, NSPH enterprise value is only twice as much.
Sometimes sarcasm doesn't work on message board. My point is that analysts aren't issuing their recommendations based on a desire to help you. They have their own agenda and would like you to either buy or sell, after they have established positions.
So you bought your house with cash? Debt to capital isn't a useful measure. Debt to cash flow is useful. What am I doing? Why am I bothering to provide you with a free education?
At least someone is finally aware that valuation is too low. It is good to talk about the long term, but if the short term is consistently in the wrong direction, the long term goals become that much harder to achieve.
Or someone who owned the convertible thought he saw a buy out on the horizon and didn't want to miss it by holding the bonds. 6% is a nice return, but that much can be be gained in an hour with the right news. Just speculating...